Picture of Auxly Cannabis logo

XLY — Auxly Cannabis News Story

0.000.00%
ca flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapSuper Stock

Canada's Auxly Cannabis Group Q1 revenue, adj EBITDA rise

Overview

Canada cannabis consumer goods firm's Q1 revenue grew 22% yr/yr

Q1 adjusted EBITDA rose 65% yr/yr, driven by improved gross profits

Company announced share repurchase program for up to 68.9 mln common shares

Outlook

Auxly plans C$10 mln to C$12 mln in capital projects at Leamington facility in 2026

Result Drivers

COST REDUCTIONS - Co attributed improved gross margin to manufacturing process improvements, higher cultivation yields, efficiency gains at Charlottetown facility, and strategic procurement initiatives

OPERATING EFFICIENCY - SG&A expenses rose in absolute terms to support higher sales, but declined as a percentage of revenue, indicating improved efficiency

Company press release: ID:nCNWrWQnFa

Key Details

MetricBeat/MissActualConsensus Estimate
Q1 RevenueBeatC$39.80 mlnC$37.90 mln (1 Analyst)
Q1 Net IncomeC$3.50 mln
Q1 Adjusted EBITDAC$12.30 mln
Analyst Coverage The one available analyst rating on the shares is "buy" The average consensus recommendation for the pharmaceuticals peer group is "buy" Wall Street's median 12-month price target for Auxly Cannabis Group Inc is C$0.25, about 78.6% above its May 13 closing price of C$0.14 The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 14 three months ago For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com. (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Auxly Cannabis

See all news